1 The EIC Accelerator Project

EIC Accelerator Program Overview

The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support small and medium-sized enterprises (SMEs) and startups in Europe that are developing groundbreaking innovations, particularly in the DeepTech sector. The program aims to foster the growth of high-potential companies by providing financial support and guidance to help them scale their innovative solutions in the market.

Funding Structure

The EIC Accelerator offers a dual funding structure, which includes both grants and equity investments.

Purpose and Impact

The EIC Accelerator plays a crucial role in the European DeepTech and startup ecosystem by addressing the funding gap that often exists for innovative companies. Many startups face challenges in securing private investment due to the high-risk nature of their projects. By providing substantial financial backing and mentorship, the EIC Accelerator empowers startups to move from the concept stage to commercialization. This, in turn, fosters innovation, creates jobs, and contributes to the overall economic growth in Europe.

Role in Scaling and Funding

The EIC Accelerator not only provides financial support but also offers strategic guidance and access to a network of investors and industry experts. This dual approach helps companies build investor confidence and attract additional funding from the private sector. By leveraging the credibility associated with EIC support, startups can improve their chances of securing further investments, which is essential for scaling operations and achieving long-term success.

Case Study: Womed SAS and the WOMED Project

Company Overview: Womed SAS is a French startup that has developed an innovative approach to drug delivery through its project named WOMED. The company’s focus is on creating a biodegradable polymer-based drug-delivery platform designed for intrauterine applications.

Project Overview - WOMED: The WOMED project aims to revolutionize the delivery of pharmaceutical compounds directly into the uterus, thereby enhancing the efficacy of treatments while minimizing side effects. The drug delivery system utilizes biodegradable polymers, allowing for sustained release of medications over time, which can significantly improve patient outcomes.

Technology Background: The technology behind WOMED involves sophisticated polymer chemistry, where biocompatible and biodegradable materials are engineered to form a drug delivery system that can be safely implanted. The polymers used in the WOMED project are designed to dissolve naturally within the body, eliminating the need for surgical removal. This approach not only reduces the risk of complications associated with traditional drug delivery methods but also facilitates targeted treatment, particularly for conditions such as endometriosis or uterine fibroids.

The project has the potential to transform the landscape of gynecological treatments by offering a less invasive, more effective alternative to existing therapies. The development of such technologies is crucial as it aligns with the growing demand for personalized medicine and targeted treatment strategies.

Conclusion

The EIC Accelerator program serves as a vital catalyst for innovation within the European startup ecosystem, exemplified by the successful case of Womed SAS and its WOMED project. By providing access to substantial funding and strategic resources, the program enables groundbreaking technologies to reach the market, ultimately contributing to improved healthcare solutions and enhanced patient outcomes. With its focus on deep tech and innovative startups, the EIC Accelerator continues to play a pivotal role in fostering economic growth and technological advancement in Europe.

2 The Funding Rounds

# Womed SAS: EIC Accelerator Funding Analysis

Womed SAS, a French healthcare technology company, was among the 42 companies selected to receive funding from the European Innovation Council (EIC) Accelerator program following the November 8, 2023 cut-off. The results of this funding round were officially published on February 28, 2024, with a total budget allocation of €285 million distributed among the successful applicants.

EIC Accelerator Funding Details

Womed SAS participated in the highly competitive EIC Accelerator program, which had a combined success rate of approximately 3.9% for Step 2 and Step 3 of the application process. The program's November 2023 cut-off was notable for its support of innovative companies across Europe, with French companies representing 12% of the selected businesses in a similar earlier 2023 call.

While the exact funding amount specifically allocated to Womed SAS is not detailed in the available information, the company was part of the funding distribution that followed these patterns:

• Funding Type Distribution: 62% of the selected companies received blended finance (combination of grants and equity investments), 29% received grant-first funding, 7% received grant-only funding, and 2% received equity-only funding.
• Timeline: The grant financing for selected companies was expected to be disbursed within two to three months after the announcement (approximately April-May 2024), while equity investment decisions were to be made within two months depending on urgency.

Investment Structure

As part of the EIC Accelerator program, Womed SAS likely benefited from the EIC Fund's investment approach. The EIC Fund serves as the dedicated investment vehicle for EIC Accelerator companies and typically attracts additional investors, increasing the overall investment to over three times the initial EIC investment on average.

The funding provided through the EIC Accelerator is designed to support startups and SMEs in bringing their innovations to market, with a focus on game-changing technologies. This support is particularly valuable for deep tech companies like Womed SAS that are developing cutting-edge medical technologies.

Market Context

Womed SAS secured this funding during a period when the European venture capital landscape was showing signs of recovery. By early 2025, private capital markets were experiencing improvements in both valuations and round sizes across different funding series, suggesting a favorable environment for further fundraising activities beyond the EIC support.

The company's selection as an EIC Accelerator recipient also positions it well for potential follow-on funding, as the program's endorsement often serves as validation for other investors looking at deep tech opportunities in the healthcare sector.

Sources: - https://rasph.com/unveiling-the-latest-eic-accelerator-results-a-comprehensive-analysis-november-8th-2023-cut-off-february-2024-release/

• https://rasph.com/latest-eic-accelerator-results/
• https://www.strata.team/eic-accelerator-winners-and-statistics-march-2023-e261-million-for-european-deep-techs/
• https://horizoneuropencpportal.eu/news/eic-accelerator-final-2023-cut-funds-42-companies-eu285-million
• https://nvca.org/wp-content/uploads/2025/01/Q4-2024-PitchBook-NVCA-Venture-Monitor.pdf

3 The Press Releases

Womed SAS: An EIC Accelerator Winner

Womed SAS, a French company, was among the winners of the EIC Accelerator funding for the November 8, 2023, cut-off. This prestigious funding is part of the European Innovation Council's (EIC) efforts to support groundbreaking innovations across Europe.

Company Overview

Womed SAS is known for its innovative intrauterine biodegradable polymer-based drug delivery system, which represents a significant advancement in medical technology. However, specific details about the company's technology, partnerships, or team updates are not readily available from the press releases or public information available.

Funding and Impact

The EIC Accelerator provides a combination of grants and equity investments to support innovative startups and SMEs. Womed SAS's inclusion in this program highlights its potential to bring impactful medical innovations to the market. The funding will likely enhance the company's ability to scale up its operations and further develop its innovative drug delivery system.

Press Releases and Updates

As of now, there are no specific press releases or updates available on Womed SAS's website (womedtech.com) directly related to the EIC Accelerator funding or other significant developments. Typically, press releases provide detailed insights into a company's achievements, partnerships, or technological advancements, but such information is not currently publicly available for Womed SAS.

Conclusion

Womed SAS's success in securing EIC Accelerator funding underscores its commitment to innovative healthcare solutions. While detailed information on the company's recent developments or partnerships is limited, its inclusion in the EIC Accelerator program is a testament to its potential for growth and innovation in the medical technology sector.

Sources

• Unveiling the Latest EIC Accelerator Results: A Comprehensive Analysis
• Latest EIC Accelerator Results
• EIC Accelerator 8 November Cut-Off

4 The Technology Advancements

Company Overview: Womed SAS

Womed SAS is a French company specializing in uterine health, particularly focusing on innovative treatments for uterine pathologies such as infertility, endometriosis, fibroids, and uterine bleeding. The company has developed a proprietary polymer technology platform for intrauterine implantation and local active ingredient administration. Its flagship product, Womed Leaf®, is designed to prevent and treat intrauterine adhesions (IUAs), which are a significant cause of infertility and recurrent miscarriages.

Recent Advancements

Following the EIC Accelerator funding in November 2023, Womed SAS has made significant strides in advancing its technology and market presence. Notably, the company announced the launch of Womed Leaf® in Europe, marking a major milestone in its global expansion. This medical device is the first physical barrier proven to prevent IUAs effectively, offering hope to many women facing fertility issues.

Market Demonstration

Womed Leaf has been demonstrated through successful clinical trials, including the PREG2 randomized clinical study involving 160 patients. This trial showcased the device's effectiveness in preventing IUAs, which are common after procedures like dilation and curettage or fibroid removal. The partnerships with Kebomed Europe and Saesco Medical have facilitated the distribution of Womed Leaf across various European countries, enhancing its market presence and accessibility to potential customers.

Technology Improvements and New Features

While specific new features have not been detailed, Womed continues to develop its intrauterine drug delivery systems. These advancements aim to address diverse uterine health challenges, including endometriosis and fibroids, leveraging its proprietary polymer technology.

Clinical Trials and Scientific Publications

Womed SAS has been involved in several clinical trials, with ongoing research aimed at expanding its treatment portfolio. However, specific new publications or trials initiated since receiving the EIC funding have not been detailed in the available information.

Patent Filings

The company continues to innovate, with a focus on its drug pipeline and technology platform. Details on recent patent filings are not specified, but Womed's commitment to advancing its proprietary polymer technology suggests ongoing efforts in intellectual property development.

Conclusion

Womed SAS has demonstrated significant progress in the development and commercialization of its innovative uterine health solutions. With the successful launch of Womed Leaf in Europe and ongoing research into additional treatments, the company is poised to make a substantial impact in the field of women's health.

Sources: - Womed Launches Female Fertility Preserving Device in Europe

• WOMED | Women's health tech
• Womed SAS - Drug pipelines, Patents, Clinical trials

5 The Partnerships and Customers

Despite extensive research, specific information about Womed SAS's partnerships, customers, or new relationships since receiving the EIC Accelerator funding in November 2023 is not available. However, the EIC Accelerator funding is a significant boost for innovative companies like Womed SAS, as it supports scaling and technology advancements.

General Impact of EIC Accelerator Funding

The EIC Accelerator funding is designed to support innovative startups and small businesses in scaling their operations and advancing their technologies. For companies like Womed SAS, this funding can be crucial in:

• Scaling Technologies: The funding can be used to enhance and scale the company's technology offerings, potentially leading to more efficient and effective solutions.
• Market Positioning: By supporting further development and scaling, the funding helps position Womed SAS more competitively in the market, potentially expanding its customer base.
• Partnerships and Collaborations: While specific partnerships for Womed SAS are not detailed, companies that receive such funding often find opportunities to form new alliances or strengthen existing ones, which can contribute to technological advancements and market growth.

Nature of Relationships and Purpose

In general, relationships formed by companies after receiving funding like the EIC Accelerator often involve collaborations with other technology firms, research institutions, or industry partners to enhance their offerings and reach new markets. These partnerships can be pivotal for technology advancements, as they facilitate knowledge sharing, resource pooling, and joint innovation efforts.

Technology Advancements and Scaling

The funding typically supports companies in advancing their technology by investing in research and development, hiring talent, and improving operational efficiency. This can lead to more sophisticated products or services that appeal to a broader customer base, contributing to the company's growth and market presence.

Conclusion

While specific details about Womed SAS's new partnerships or customers are not available, the EIC Accelerator funding is likely to play a significant role in its growth and technological advancements. As the company continues to develop its offerings and expand its market presence, forming strategic partnerships will be crucial for achieving these goals.

Sources:

• Womed Tech Official Website
• [No specific sources available for Womed SAS partnerships or customer details.]

6 The Hiring and Company Growth

Womed SAS: Recent Developments and Growth

Introduction to Womed SAS

Womed SAS is a French company that has recently emerged as a winner of the EIC Accelerator funding. Despite the lack of detailed information on Womed SAS's hiring processes or team size, the company's success in securing this prestigious funding indicates significant potential for growth and expansion.

Hiring and Team Growth

There is currently no publicly available information on Womed SAS's hiring policies, team size, or recent hires. However, securing EIC Accelerator funding typically signifies a period of strategic growth and investment in talent. Companies often use such funding to enhance their teams by hiring key positions in areas like technology, marketing, and operations.

Current Headcount and Team Size

Specific details about Womed SAS's current headcount or team size are not available. The EIC Accelerator funding often supports companies in expanding their workforce to meet increasing demands and project requirements.

Are They Currently Hiring?

While there is no direct information indicating that Womed SAS is actively hiring, the receipt of EIC Accelerator funding suggests that the company is likely to be in a phase of expansion, which may include hiring new team members.

Growth and Expansion

The EIC Accelerator funding is a significant catalyst for growth, allowing companies to scale their operations and expand into new markets. Womed SAS's success in securing this funding indicates a strong potential for future growth.

Key Positions and New Team Members

Although specific details about recent hires are not available, companies that receive this type of funding often focus on hiring key talent in areas critical to their expansion plans. This could include roles in technology development, business strategy, and marketing.

Impact on the Future of the Company

The EIC Accelerator funding will likely enable Womed SAS to accelerate its product development, enhance its market presence, and scale its operations. New team members will play a crucial role in executing these strategies, contributing to the company's ability to innovate and expand its offerings.

Major Changes in Management or Founding Team

There is no publicly available information on recent changes in Womed SAS's management or founding team. However, the receipt of significant funding often leads to strategic appointments that can help drive the company's growth and vision.

Conclusion

Womed SAS's success in the EIC Accelerator program positions it for significant growth and expansion. While specific details about hiring and team size are not currently available, the company is likely to be in a period of strategic development and talent acquisition.

Sources

• EIC Accelerator
• Womed Tech Website
• EIC Accelerator Funding
• European Innovation Council
• Note: Specific information about Womed SAS was not found in search results; the content is based on general trends and expectations for companies receiving EIC Accelerator funding.

7 The Media Features and Publications

Womed SAS: Post-EIC Accelerator Funding Visibility Womed SAS, a French medical innovator developing biodegradable intrauterine drug delivery systems, emerged as an EIC Accelerator winner in the November 8th, 2023 cut-off round. While detailed media coverage specific to the company remains limited in publicly available records, the following summarizes its documented visibility post-funding:

Media Features & Publications

Publicly indexed publications directly naming Womed SAS are sparse based on current data. However, its selection as an EIC Accelerator winner has been prominently highlighted by funding analysis platforms like Rasph, which listed it among 42 grantees awarded €285 million collectively.

---

Podcasts & Interviews

No podcasts or interviews featuring Womed SAS’s team were identified in the search results. Notably, a similarly named podcast (The WoMed) focuses on women in medicine but is unrelated to the company.

---

Conference Participation & Events

While specific conference appearances for Womed SAS are not detailed in available sources, EIC Accelerator winners often leverage funding to increase visibility at industry events like Bio-IT World Expo. The company’s focus on women’s health innovations positions it for potential participation in medtech or biopolymer-focused forums.

---

Post-Funding Trajectory

As part of the EIC portfolio, Womed SAS likely benefits from EU-supported networking and pitch opportunities. The November 2023 cohort saw heightened competition (1,083 applicants), underscoring the company’s validated technical merit.

---

Sources

• Unveiling the Latest EIC Accelerator Results: A Comprehensive Analysis
• The WoMed Podcast (unrelated entity)
• Bio-IT World Expo 2025 Speaker Biographies (no direct mention of Womed SAS)
• EIC June 2023 Winners Context

Note: For real-time updates about conferences or media mentions beyond February 2024 (the latest data here), monitoring press releases from womedtech.com or EU Cordis would be advisable.